Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/54056
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Breast cancer risk reduction and membrane-bound catechol o-methyltransferase genetic polymorphisms |
Author: | Ji, Y. Olson, J. Zhang, J. Hildebrandt, M. Wang, L. Ingle, J. Fredericksen, Z. Sellers, T. Miller, W. Dixon, J. Brauch, H. Eichelbaum, M. Justenhoven, C. Hamann, U. Ko, Y. Bruning, T. Chang-Claude, J. Wang-Gohrke, S. Schaid, D. Weinshilboum, R. |
Citation: | Cancer Research, 2008; 68(14):5997-6005 |
Publisher: | Amer Assoc Cancer Research |
Issue Date: | 2008 |
ISSN: | 0008-5472 1538-7445 |
Statement of Responsibility: | Yuan Ji, Janet Olson, Jianping Zhang, Michelle Hildebrandt, Liewei Wang, James Ingle, Zachary Fredericksen, Thomas Sellers, William Miller, J. Michael Dixon, Hiltrud Brauch, Michel Eichelbaum, Christina Justenhoven, Ute Hamann, Yon Ko, Thomas Brüning, Jenny Chang-Claude, Shan Wang-Gohrke, Daniel Schaid and Richard Weinshilboum |
Abstract: | Catechol O-methyltransferase (COMT)-catalyzed methylation of catecholestrogens has been proposed to play a protective role in estrogen-induced genotoxic carcinogenesis. We have taken a comprehensive approach to test the hypothesis that genetic variation in COMT might influence breast cancer risk. Fifteen COMT single nucleotide polymorphisms (SNPs) selected on the basis of in-depth resequencing of the COMT gene were genotyped in 1,482 DNA samples from a Mayo Clinic breast cancer case control study. Two common SNPs in the distal promoter for membrane-bound (MB) COMT, rs2020917 and rs737865, were associated with breast cancer risk reduction in premenopausal women in the Mayo Clinic study, with allele-specific odds ratios (OR) of 0.70 [95% confidence interval (CI), 0.52-0.95] and 0.68 (95% CI, 0.51-0.92), respectively. These two SNPs were then subjected to functional genomic analysis and were genotyped in an additional 3,683 DNA samples from two independent case control studies (GENICA and GESBC). Functional genomic experiments showed that these SNPs could up-regulate transcription and that they altered DNA-protein binding patterns. Furthermore, substrate kinetic and exon array analyses suggested a role for MB-COMT in catecholestrogen inactivation. The GENICA results were similar to the Mayo case control observations, with ORs of 0.85 (95% CI, 0.72-1.00) and 0.85 (95% CI, 0.72-1.01) for the two SNPs. No significant effect was observed in the GESBC study. These studies showed that two SNPs in the COMT distal promoter were associated with breast cancer risk reduction in two of three case control studies, compatible with the results of functional genomic experiments, suggesting a role for MB-COMT in breast cancer risk. |
Keywords: | Catechol-O-methyltransferase COMT MB-COMT S-COMT breast cancer risk genetic polymorphism SNPs functional genomics |
DOI: | 10.1158/0008-5472.CAN-08-0043 |
Published version: | http://dx.doi.org/10.1158/0008-5472.can-08-0043 |
Appears in Collections: | Aurora harvest Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.